Enterprise Value
736.4M
Cash
343.6M
Avg Qtr Burn
-30.23M
Short % of Float
17.89%
Insider Ownership
12.96%
Institutional Own.
91.96%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TNG260( CoREST complex inhibitor) w/ pembrolizumab Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
TNG462 ( PRMT5 inhibitor) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
TNG908 ( PRMT5 inhibitor) Details Cancer, Solid tumor/s, Glioblastoma | Phase 1/2 Data readout | |
TNG348 (USP1 inhibitor) Details Cancer, Ovarian cancer, Breast cancer, Prostate cancer, Pancreatic cancer | Failed Discontinued |